Table 1.
Treatment parameters.
Fig 1.
Markov model flow diagram.
Table 2.
Health state transition rates.
Table 3.
Health state costs and utility estimates.
Fig 2.
Screening flow diagram showing the derivation of the number of patients screened and allocated treatment across all patient populations.
Table 4.
Base case cost-effectiveness results.
Table 5.
Subgroup cost-effectiveness results.
Fig 3.
The number of events avoided and the incremental costs associated with a screening and treatment program.
Fig 4.
The relationship between the cost-effectiveness of screening and treatment, the prevalence of HCV amongst the general population and the rate of therapy uptake post diagnosis.
Table 6.
The relationship between the timing of treatment post-diagnosis and the cost-effectiveness of a screening and treatment program.